Doctors of interest. Recipients of suspect drug-company payments academic medical centers, have drawing attention of federal fraud enforcers.
As the federal government begins to focus more on wasteful healthcare spending, doctors' relationships with drug companies are coming under scrutiny. Many times, those relationships are legitimate, says Mary Riordan, left, a senior counsel to HHS' inspector general's office. "There are other situations where the relationship between the doctor and the manufacturer is suspect".